Junshi Biosciences: Net loss attributable to parent company in 2025 is 874 million yuan

2026-03-29 14:46:57

Junshi Biosciences released its performance report, with total operating revenue of 2.498 billion yuan for the year 2025, an increase of 28.23% year-on-year. In 2025, the company’s core product, Toripalimab injection (brand name: Tuoyi), saw a significant year-on-year sales revenue increase of approximately 37.72% in the domestic market. During the reporting period, the company’s operating revenue grew compared to the same period last year, mainly due to the substantial year-on-year increase in sales revenue of its core product, Toripalimab injection (brand name: Tuoyi), in the domestic market. The net profit attributable to the parent company’s owners was -874 million yuan, compared to -1.281 billion yuan in the same period last year.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes